Should I buy Manulife US stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Manulife Financial for over three years. Every month, hundreds of thousands of users in Singapore trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Manulife Financial.

What is Manulife US?

Manulife US stock price

The price of Manulife US stock is rising this week. The current share price on the NYSE is $31.88, with a positive 24-hour change of +1.37% and a slight weekly decline of -0.19%. Manulife US now boasts a market capitalization of $54.45 billion, with an average daily volume of 2.42 million shares over the past three months. The Price/Earnings (P/E) Ratio stands at 16.43, while the dividend yield is currently 4.02%, and its stock beta is 1.06. This combination of steady volume, attractive yield, and moderate volatility offers appealing opportunities for Singapore investors.

Our full analysis of the Manulife US stock

After a thorough review of Manulife US’s most recent financial results and its impressive stock performance over the past three years, we have consolidated a wealth of financial metrics, technical indicators, industry data, competitor benchmarking, and cutting-edge algorithmic models to present a unified perspective. This composite analysis gives SG-based investors a rigorous, data-driven assessment of where Manulife US stands both now and in the evolving market landscape. So, why might Manulife US stock once again become a strategic entry point into the global insurance and asset management sector in 2025?

Recent performance and market context

Manulife US has maintained robust price stability and growth momentum in 2025, trading at USD 31.88 on the NYSE as of July, after a solid annual return of +18.8% and a steady 6-month gain of +3.95%. Daily and weekly price swings remain contained within narrow bands, a sign of reduced volatility and strong institutional interest. This remarkable stability came despite shifting global interest rate trends, underscoring the market’s growing confidence in Manulife US’s core earnings resilience and its North American-Asian diversification. The company’s strong performance has also been bolstered by key positive events, including the appointment of a dynamic new CEO, Phil Witherington, and significant strategic initiatives such as the C$13 billion reinsurance agreement with Global Atlantic and a concurrent C$1.2 billion share buyback program. These decisive moves have not only strengthened the capital base but have also catalyzed bullish sentiment across global financial hubs, including Singapore. Moreover, the insurance sector is enjoying cyclical tailwinds as Asia’s middle class expands and global savings patterns shift toward diversified, long-duration products—a theme particularly relevant for SG-based investors seeking exposure abroad.

Technical analysis

From a technical perspective, the signals for Manulife US point decisively upward. The Relative Strength Index (RSI) sits at a balanced 54.4, reflecting neither overheated nor oversold conditions and leaving ample room for upward movement. MACD indicators register a subtly positive “buy” bias at 0.01, complementing the trend of consecutive closes above the 5-, 20-, 50-, 100-, and 200-day moving averages ($31.85, $31.75, $31.80, $31.48, and $31.66 respectively). This technical structure demonstrates entrenched short- and medium-term bullishness, reinforcing the case for strategic accumulation. Importantly, the stock now holds just above a strong support level at $31.52, with the next resistance seen at $31.90—a favorable position for new entrants. Further, technical consensus among leading analysts and algorithmic models currently flags Manulife US as a “Strong Buy,” which is rare for such a large-cap insurer and highlights the convergence of momentum and fundamentals.

Fundamental analysis

Drilling down into the fundamentals, Manulife US continues to deliver high-quality, recurring revenue streams and robust profitability. In Q1 2025, the firm posted revenue of C$8.68 billion and core earnings of C$1.8 billion, displaying only a minor 1% contraction on a constant currency basis despite broader market volatility—an impressive feat for a multi-line insurer operating across continents. Even though net income fell (reflecting non-operational, market-related factors), adjusted core EPS came in at $0.99—up 3% year-on-year—and above consensus forecasts. Notably, the annualized premium equivalent (APE) sales surged 37%, confirming rising demand across Asia and North America.

Valuation is another compelling factor. With a trailing P/E ratio of 16.43 (and a forward consensus below 15), Manulife US is attractively priced against both regional peers and its own historical averages, offering a valuable margin of safety. This multiple looks even more appealing when factoring in a quarterly dividend yield of 4.02%—considered highly competitive in today’s global yield-starved environment—especially since Manulife US has a long-standing and credible commitment to consistent, growing distributions. Structurally, the company’s diversified business model—spanning insurance, wealth management, and global asset management—gives it revenue durability, innovation capacity, and cross-market synergies. Its deep-rooted Asian presence, leadership in digital transformation, and recognized AI adoption reinforce Manulife US’s edge in product innovation and operational scale. The strong “brand premium” and extensive institutional investor following further underpin both price support and upside.

Volume and liquidity

Liquidity remains a standout feature: Manulife US trades an average of 2.42 million shares per day on the NYSE alone, with seamless execution and tight spreads. A public float of over 1.71 billion shares allows for dynamic price discovery and keeps the stock accessible to both large institutions and retail investors in Singapore and internationally. This liquidity translates into robust market confidence and limits execution risk, particularly important for investors considering sizable allocations or systematic accumulation. The stock’s presence on both the TSX and NYSE also facilitates cross-border flows, offering additional flexibility for those investing from Singapore.

Catalysts and positive outlook

A rich pipeline of catalysts sets the stage for Manulife US’s next growth cycle. The recent transition to CEO Phil Witherington comes with a strong track record in Asian operations and group finance, likely accelerating ongoing digital and product innovation agendas. Equally important is the C$13 billion reinsurance agreement with Global Atlantic, which frees up capital for reinvestment and supports a major C$1.2 billion buyback—directly enhancing shareholder value.

Emerging as one of the most advanced AI-enabled financial institutions (named #1 Life Insurance Company for AI Maturity by Evident), Manulife US leverages data analytics in underwriting, claims, and customer engagement. Future-forward initiatives in digital distribution, algorithmic portfolio management, and ESG-focused investment products position Manulife US at the forefront of sustainable finance trends—a differentiator in both Asian and North American markets.

The company is also poised to benefit from structural mega-trends: the expansion of Asia’s middle class, the accelerating shift from savings to investment solutions, and the burgeoning demand for private retirement and health products in rapidly urbanizing Asian economies. Regulatory support for long-term insurance plus the ongoing decline in global interest rates further underpin sector-wide bullishness. In sum, these catalysts may drive both earnings visibility and multiple expansion for Manulife US over the next cycle.

Investment strategies

For investors in Singapore, Manulife US offers flexibility across different timeframes:

• Short-term traders: Can capitalize on near-term bullish momentum, frequent “buy” signals from technical indicators, and the likely impact from upcoming Q2 results.
• Medium-term participants: May prefer to build exposure ahead of expected earnings growth, the full effect of buybacks, and as digital initiatives start to manifest in both Asia and North America.
• Long-term investors: Have the opportunity to benefit from defensive cash flows, consistent dividend payouts, persistent demand for insurance and investment products in growth regions, and Manulife US’s proven ability to scale global innovations.

Given that the stock trades just shy of both its 52-week high ($33.07) and consensus analyst target ($35.04), current price levels may represent ideal entry points ahead of the next leg up—especially as the technical structure points toward continued accumulation and the business model offers resilience through various market cycles.

Is it the right time to buy Manulife US?

In summary, Manulife US seems to represent an excellent opportunity for investors looking for yield, stability, and long-term growth within a global financial leader. Its multifaceted strengths—high quality recurring revenue, robust liquidity, a strong capital position, proven leadership, and a business model recalibrated for the future—all justify renewed interest. The technical and fundamental signals are aligned for a new bullish phase, while sector trends and regional expansion offer substantial upside. For investors in Singapore eager to participate in the global insurance and wealth management boom, Manulife US may well be entering one of its most attractive setups in recent years—combining stability, income, and innovation potential.

With its consistent performance, compelling catalysts, and measured positioning, Manulife US offers a timely and promising opportunity to ride the next phase of growth in the insurance and asset management sector, making it a stock that deserves serious consideration from thoughtful, forward-looking investors.

How to buy Manulife US stock in Singapore?

Buying Manulife US stock online is simple and secure through any regulated broker authorised in Singapore. Investors can choose between two main approaches: spot buying, which means directly owning Manulife US shares, or CFD trading, which lets you speculate on price movements with leverage but without owning the stock. Both options offer quick, transparent access and investor protection, making it easy to get started. For more information on selecting the best broker for your needs, see our detailed comparison further down the page.

Spot buying

Buying Manulife US stock “cash” means purchasing real shares that you will hold in your investment account. Usually, brokers charge a fixed commission per order (often between SGD $4 and $10), plus possible minimal foreign exchange fees.

Gain scenario

If the Manulife US share price is $31.88 USD, you can buy around 31 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFDs (Contracts for Difference) allow you to trade on the price movements of Manulife US shares without owning the actual stock. You’ll pay a spread (difference between buy and sell price), and possibly overnight financing if your position is held for more than a day.

CFD Gain Scenario: Manulife US Shares with Leverage

You open a CFD position on Manulife US shares, with 5x leverage.

This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before investing, always compare brokers for fees, available markets, and investment conditions—see our comparison table lower on the page. Ultimately, choosing between cash buying and CFDs depends on your investment objectives and risk appetite. Both methods offer a professional, simple way to access Manulife US stock directly from Singapore.

7 tips for buying Manulife US stock

The latest news about Manulife US

Manulife US reports continued growth in Asian insurance and wealth management business. In the past week, Manulife US confirmed robust momentum in its Asian operations, specifically highlighting growing insurance and asset management revenues from Singapore and Southeast Asia. The company reported increased distribution of its health and protection products through local bancassurance partnerships, further deepening its regional footprint and supporting recurring premium growth.

Recent leadership transition brings renewed strategy focus for Asia, including Singapore. With the appointment of Phil Witherington as CEO in May 2025, Manulife US has placed additional focus on strengthening its Asian businesses. Official communications in the last seven days reiterate the group’s commitment to digital transformation and customer-centric products for Singaporean policyholders, positioning the brand for further regional market share gains.

Positive technical indicators and strong momentum support Manulife US stock outlook. Current technical analysis reveals the stock remains in a clear uptrend, trading above its 20-, 50-, and 200-day moving averages with a neutral RSI of 54.40. This healthy technical positioning has sustained investor demand and facilitated strong daily trading volumes on the NYSE, a signal of international investor confidence—including from Southeast Asian markets.

Manulife US’s recent dividend announcement appeals to Singapore investors looking for yield. This week, Manulife US confirmed the next quarterly dividend at $0.32 USD per share, maintaining its steady payout. Given Singapore’s tax regime—where overseas dividends are generally not taxed for individual investors—Manulife US remains attractive for those seeking reliable, tax-efficient dividend income from global stocks.

Manulife US prepares for upcoming earnings as analysts reiterate positive regional outlook. In anticipation of the Q2 earnings release scheduled for August 6, 2025, analysts have reaffirmed a ‘Moderate Buy’ view, citing resilient core earnings and upside from Asia-driven growth. Market commentary in Singapore notes particular interest in the company’s success in integrating AI and digital solutions for regional clients, which is expected to further enhance profitability and operational efficiency.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.